Nevro Corp. (NYSE:NVRO) Director Michael F. Demane Sells 5,000 Shares

Nevro Corp. (NYSE:NVRO) Director Michael F. Demane sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $93.50, for a total transaction of $467,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Michael F. Demane also recently made the following trade(s):

  • On Wednesday, September 27th, Michael F. Demane sold 5,000 shares of Nevro Corp. stock. The shares were sold at an average price of $91.50, for a total transaction of $457,500.00.
  • On Wednesday, September 13th, Michael F. Demane sold 5,000 shares of Nevro Corp. stock. The stock was sold at an average price of $89.50, for a total transaction of $447,500.00.
  • On Monday, September 11th, Michael F. Demane sold 25,000 shares of Nevro Corp. stock. The stock was sold at an average price of $87.73, for a total value of $2,193,250.00.

Shares of Nevro Corp. (NYSE NVRO) opened at 91.49 on Friday. The company’s market capitalization is $2.69 billion. Nevro Corp. has a 12 month low of $65.82 and a 12 month high of $102.26. The firm has a 50-day moving average price of $89.55 and a 200-day moving average price of $83.72.

Nevro Corp. (NYSE:NVRO) last announced its quarterly earnings data on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.11). The company had revenue of $78.02 million during the quarter, compared to analyst estimates of $77.75 million. Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. Nevro Corp.’s revenue was up 40.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.31) earnings per share. On average, equities research analysts predict that Nevro Corp. will post ($1.16) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Nevro Corp. (NYSE:NVRO) Director Michael F. Demane Sells 5,000 Shares” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://ledgergazette.com/2017/10/21/michael-f-demane-sells-5000-shares-of-nevro-corp-nvro-stock.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. acquired a new position in Nevro Corp. in the 3rd quarter valued at $454,000. Dynamic Technology Lab Private Ltd increased its stake in shares of Nevro Corp. by 8.9% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 6,857 shares of the medical equipment provider’s stock valued at $510,000 after purchasing an additional 559 shares during the last quarter. Asymmetry Capital Management L.P. increased its stake in shares of Nevro Corp. by 122.9% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 60,893 shares of the medical equipment provider’s stock valued at $4,532,000 after purchasing an additional 33,575 shares during the last quarter. Sterling Capital Management LLC bought a new position in shares of Nevro Corp. in the 2nd quarter valued at $233,000. Finally, Ameritas Investment Partners Inc. increased its stake in shares of Nevro Corp. by 17.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock valued at $181,000 after purchasing an additional 358 shares during the last quarter.

NVRO has been the topic of a number of analyst reports. Zacks Investment Research raised Nevro Corp. from a “strong sell” rating to a “buy” rating and set a $96.00 price target on the stock in a research note on Wednesday, August 2nd. Canaccord Genuity reissued a “buy” rating and issued a $120.00 price target on shares of Nevro Corp. in a research note on Wednesday, July 5th. Northland Securities reaffirmed a “buy” rating and set a $96.00 target price on shares of Nevro Corp. in a research note on Tuesday, August 8th. BMO Capital Markets reaffirmed a “buy” rating and set a $106.00 target price on shares of Nevro Corp. in a research note on Friday, September 1st. Finally, BidaskClub raised Nevro Corp. from a “sell” rating to a “hold” rating in a research note on Saturday, October 7th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Nevro Corp. currently has a consensus rating of “Hold” and an average price target of $101.25.

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Insider Buying and Selling by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply